| scholarly article | Q13442814 |
| P50 | author | Age-Related Eye Disease Study Research Group | Q83234373 |
| P2093 | author name string | Michael L Klein | |
| Frederick L Ferris | |||
| Anne S Lindblad | |||
| Traci E Clemons | |||
| Gary R Gensler | |||
| Patricia C Lloyd | |||
| Jane R Armstrong | |||
| P2860 | cites work | A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 | Q24544001 |
| Measuring agreement in method comparison studies | Q28145208 | ||
| Prevalence of age-related macular degeneration in the United States | Q29614964 | ||
| Symmetry of bilateral lesions in geographic atrophy in patients with age-related macular degeneration | Q31052836 | ||
| Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study | Q31099429 | ||
| Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration | Q33209200 | ||
| Modelling the natural history of geographic atrophy in patients with age-related macular degeneration | Q33227050 | ||
| Issues in quantifying atrophic macular disease using retinal autofluorescence | Q33249400 | ||
| Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration | Q33269883 | ||
| The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. | Q33774150 | ||
| Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report no. 14 | Q34655503 | ||
| The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. | Q34655539 | ||
| Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity | Q36886079 | ||
| The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials | Q36924781 | ||
| Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. | Q39756448 | ||
| Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2. | Q39843458 | ||
| Photopic and scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy | Q44743301 | ||
| Peripheral retinal function in age-related macular degeneration. | Q54486090 | ||
| Retinal sensitivity over drusen and nondrusen areas. A study using fundus perimetry | Q68462577 | ||
| Pathologic features of senile macular degeneration | Q68935500 | ||
| Evolution of geographic atrophy of the retinal pigment epithelium | Q69099160 | ||
| Geographic atrophy of the retinal pigment epithelium: diagnosis and vision rehabilitation | Q70876792 | ||
| Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration | Q78257646 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| geographic atrophy | Q47200750 | ||
| P304 | page(s) | 1168-1174 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | JAMA Ophthalmology | Q4787301 |
| P1476 | title | Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. | |
| P478 | volume | 127 |
| Q92456774 | A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II |
| Q24201127 | Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases |
| Q37296574 | Association between geographic atrophy progression and reticular pseudodrusen in eyes with dry age-related macular degeneration. |
| Q93047673 | Autoimmune-Mediated Retinopathy in CXCR5-Deficient Mice as the Result of Age-Related Macular Degeneration Associated Proteins Accumulation |
| Q47663159 | Automated Grading of Age-Related Macular Degeneration From Color Fundus Images Using Deep Convolutional Neural Networks. |
| Q36631736 | Automated geographic atrophy segmentation for SD-OCT images using region-based C-V model via local similarity factor. |
| Q36348003 | Automated segmentation of geographic atrophy of the retinal epithelium via random forests in AREDS color fundus images |
| Q89536479 | Burden of Illness in Geographic Atrophy: A Study of Vision-Related Quality of Life and Health Care Resource Use |
| Q21090046 | CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD |
| Q34645582 | Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry |
| Q35593465 | Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration |
| Q42800006 | Clinical characteristics, progression and risk factors of geographic atrophy |
| Q45948597 | Comparing humans and deep learning performance for grading AMD: A study in using universal deep features and transfer learning for automated AMD analysis. |
| Q36968738 | Comparison of color fundus photographs and fundus autofluorescence images in measuring geographic atrophy area |
| Q35118257 | Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. |
| Q26778247 | Current therapeutic developments in atrophic age-related macular degeneration |
| Q34378033 | Dry age-related macular degeneration: A currently unmet clinical need |
| Q64898355 | Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. |
| Q42716529 | Evaluation of Geographic Atrophy from Color Photographs and Fundus Autofluorescence Images: Age-Related Eye Disease Study 2 Report Number 11. |
| Q88345802 | Evolution of Geographic Atrophy in Participants Treated with Ranibizumab for Neovascular Age-related Macular Degeneration |
| Q38269457 | Fundus autofluorescence imaging in dry AMD: 2014 Jules Gonin lecture of the Retina Research Foundation |
| Q38388508 | GEOGRAPHIC ATROPHY: Semantic Considerations and Literature Review |
| Q28074640 | Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review |
| Q26774188 | Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects |
| Q35214092 | Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials |
| Q34002269 | Imaging geographic atrophy in age-related macular degeneration |
| Q36247080 | Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials |
| Q89687694 | Nutritional Supplements for Age-Related Macular Degeneration |
| Q37577219 | OCT minimum intensity as a predictor of geographic atrophy enlargement |
| Q35996271 | Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis |
| Q40358167 | Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy |
| Q35746909 | Potential role of lampalizumab for treatment of geographic atrophy |
| Q38607697 | Prognostic implications of imaging in atrophic macular degeneration and its use in clinical practice and clinical trial design |
| Q56243532 | Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16 |
| Q33996503 | Progression of geographic atrophy and genotype in age-related macular degeneration |
| Q33734035 | Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography |
| Q41463811 | Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide |
| Q37201004 | Reticular macular disease is associated with multilobular geographic atrophy in age-related macular degeneration |
| Q89888023 | Risk factors for progression of age-related macular degeneration |
| Q35003936 | Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials |
| Q42157638 | Simulated loss of foveal vision eliminates visual search advantage in repeated displays |
| Q38124462 | Stem cell-based treatment in geographic atrophy: promises and pitfalls |
| Q89454097 | Systemic Disease and Long-term Intraocular Pressure Mean, Peak, and Variability in Nonglaucomatous Eyes |
| Q92697703 | Systemic expression of Alu RNA in patients with geographic atrophy secondary to age-related macular degeneration |
| Q39024579 | The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target |
| Q42799991 | Therapy approaches for geographic atrophy |
| Q38978374 | Tolerability in the elderly population of high-dose alpha lipoic acid: a potential antioxidant therapy for the eye. |
| Q34662112 | Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial |
| Q36801990 | Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial |
| Q38902100 | VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR DEGENERATION. |
| Q94400988 | Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age‐related macular degeneration |
Search more.